Your browser doesn't support javascript.
loading
Mapping the genomic landscape of multidrug resistance in Plasmodium falciparum and its impact on parasite fitness.
Mok, Sachel; Yeo, Tomas; Hong, Davin; Shears, Melanie J; Ross, Leila S; Ward, Kurt E; Dhingra, Satish K; Kanai, Mariko; Bridgford, Jessica L; Tripathi, Abhai K; Mlambo, Godfree; Burkhard, Anna Y; Fairhurst, Kate J; Gil-Iturbe, Eva; Park, Heekuk; Rozenberg, Felix D; Kim, Jonathan; Mancia, Filippo; Quick, Matthias; Uhlemann, Anne-Catrin; Sinnis, Photini; Fidock, David A.
Afiliación
  • Mok S; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Yeo T; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY.
  • Hong D; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
  • Shears MJ; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Ross LS; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY.
  • Ward KE; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Dhingra SK; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY.
  • Kanai M; School of Biological Sciences, Nanyang Technological University, Singapore.
  • Bridgford JL; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • Tripathi AK; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Mlambo G; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Burkhard AY; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY.
  • Fairhurst KJ; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Gil-Iturbe E; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Park H; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY.
  • Rozenberg FD; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Kim J; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY.
  • Mancia F; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • Quick M; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • Uhlemann AC; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Sinnis P; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY.
  • Fidock DA; Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY.
bioRxiv ; 2023 Jun 03.
Article en En | MEDLINE | ID: mdl-37398288
ABSTRACT
Drug-resistant Plasmodium falciparum parasites have swept across Southeast Asia and now threaten Africa. By implementing a P. falciparum genetic cross using humanized mice, we report the identification of key determinants of resistance to artemisinin (ART) and piperaquine (PPQ) in the dominant Asian KEL1/PLA1 lineage. We mapped k13 as the central mediator of ART resistance and identified secondary markers. Applying bulk segregant analysis, quantitative trait loci mapping and gene editing, our data reveal an epistatic interaction between mutant PfCRT and multicopy plasmepsins 2/3 in mediating high-grade PPQ resistance. Susceptibility and parasite fitness assays implicate PPQ as a driver of selection for KEL1/PLA1 parasites. Mutant PfCRT enhanced susceptibility to lumefantrine, the first-line partner drug in Africa, highlighting a potential benefit of opposing selective pressures with this drug and PPQ. We also identified that the ABCI3 transporter can operate in concert with PfCRT and plasmepsins 2/3 in mediating multigenic resistance to antimalarial agents.